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More than a century after eosinophil granulocytes were
baptized by Paul Ehrlich their role in defense mechanisms
against parasitic infections and in allergic reactions has been
firmly established (1). In contrast to the wealth of func-
tional knowledge about these cells, their developmental
origin, relationship to other blood cell types, and the criti-
cal transcription factors that determine their fate have long
been elusive. Work in the 1990’s showed a key role of
both GATA and C/EBP transcription factors through ex-
periments in which their expression was enforced in trans-
formed chicken and murine cell lines. In addition, eosino-
phil-specific promoters were found to be regulated by an
interplay between these factors. In several new papers this
 
concept has been confirmed and applied to the repro-
gramming of normal human and murine cells. In addition,
two studies show that GATA-1–deficient mice lack eosin-
ophils, nicely complementing earlier work that demon-
 
strated a lack of eosinophils in C/EBP
 
 
 
-deficient mice. In
the following these papers will be discussed and interpreted
in the light of the earlier results obtained with transformed
cell systems.
 
GATA-1 As an Inducer of Eosinophil Formation.
 
In a
striking example of cellular engineering, in this issue,
Hirasawa et al. (2) have succeeded in efficiently generating
eosinophils from human fetal blood cells. To do this, they
isolated hematopoietic progenitors from human cord blood
(CD34
 
 
 
 fraction), infected them with a retrovirus that en-
codes GATA-1 (together with GFP as an indicator), and
sorted GFP-positive cells 60 h later. The cells were then
grown in SCF and GM-CSF for 5 d and subsequently for
an additional 8 d under either myeloid conditions (with the
same factors) or eosinophil conditions (with IL-5). Surpris-
ingly, perhaps, the GATA-1–transduced cells cultured un-
der myeloid conditions contained eosinophilic granules and
expressed eosinophil peroxidase as well as major basic pro-
tein but lacked myeloid markers. In contrast, the vector-
only transduced cells were predominantly myelomonocytic
and lacked eosinophil markers. GATA-2 exerted a similar
effect, while dominant negative forms of the factors (pro-
duced by fusion to the Drosophila engrailed protein as a
transcriptional repressor) completely prevented eosinophil
formation in cells grown with IL-5. They also showed that
the COOH-terminal zinc finger of GATA-1 (needed for
DNA-binding) is required for this effect, while the NH
 
2
 
-
terminal zinc finger (needed for interaction with FOG-1,
see below) is not.
Using a related approach Heyworth et al. obtained simi-
lar results with mouse bone marrow cells (Tarik Enver,
personal communication). Hematopoietic progenitors were
isolated from bone marrow (CD34
 
 
 
/c-kit
 
 
 
 fraction of cy-
clophosphamide-treated mice), infected for 2 d with a
GATA-1/GFP-encoding retrovirus, sorted for GFP ex-
pression, and cultured in soft agar. Here again, a dramatic
phenotypic shift was observed away from myelomonocytic
colonies toward colonies that consisted predominantly of
erythrocytes, eosinophils, and basophils. To ensure that this
was not due to selection of preexisting eosinophil progeni-
tors, the experiments were repeated with a hormone in-
ducible form of GATA-1 (GATA-1/ERT) and similar re-
sults were obtained. The generation of erythroid cells in
addition to eosinophils in this study cannot simply be
explained by the presence of erythropoietin in the cul-
ture medium as erythroid differentiation was also seen in
IL-3 alone. Whether this apparent discrepancy with the
GATA-1–transduced human cord blood experiments
(where only eosinophils were observed) reflects differences
between species or the tissues or vectors used for infection
remains to be seen.
 
Isolate CD34
 
 
 
 Cells, Express C/EBP
 
 
 
 and . . . Also Get
Eosinophils.
 
Using the same protocol as in the GATA-1
experiments described above, the Tsukuba group recently
described the formation of eosinophil and neutrophil gran-
ulocytes by enforced expression of C/EBP
 
 
 
 in cord blood
 
progenitors, although at lower efficiencies (3). The observa-
 
tion that eosinophils can be obtained from CD34
 
 
 
 cord
blood cells with both a zinc finger-type and a leucine zipper-
 
type transcription factor may at first seem paradoxical.
Assuming that eosinophils are specified by the coexpression
of both GATA-1 and C/EBP
 
 
 
 factors (see also below), the
observations can be explained by the following two models
(Fig. 1). In model A, the two transcription factors act on a
homogeneous population of cells. This could be a common
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myeloid precursor that is both GATA-1, C/EBP
 
 
 
 low/
negative, and in this scenario expression of either (GATA-1
or C/EBP
 
 
 
) would lead to the up-regulation of the other
factor (another target could be a population of committed
immature eosinophils but this is a possibility that we con-
sider less likely; see below). Alternatively, (model B) each
of the two factors could affect a distinct cell type within the
CD34
 
 
 
 population: one consisting of a precursor that is
GATA-1
 
 
 
 
 
but C/EBP
 
 
 
 
 
, possibly representing a granulo-
cyte/macrophage progenitor (GMP); and another that is
C/EBP
 
 
 
 but GATA-1
 
 
 
, possibly representing a megakary-
ocytic/erythroid progenitor (MEP). Transduction with
GATA-1 would complement C/EBP
 
 
 
 in the myeloid cells
and C/EBP
 
 
 
 would complement GATA-1 in the MEP
cells, in each case leading to the outgrowth of eosinophils.
A combination of models A and B is also possible. In sup-
port of the second model is the fact that CD34 is expressed
not only by multipotent progenitors, but also by commit-
ted myeloid and erythroid precursors (for a review, see ref-
erence 4). In the following we will discuss experiments,
obtained with a transformed cell system, that additionally
favor model B.
 
GMP-type Myeloid Progenitors and MEP-type Progenitors
Can Be Converted Into Eosinophils by GATA-1 and C/EBP,
Respectively.
 
The first clue as to the origins of eosinophils
came from the serendipitous finding that phorbolester
treatment of E26 leukemia virus-transformed chicken cells
converts them into eosinophils and myeloblasts in a con-
 
centration-dependent manner (5, 6; Fig. 2 A). These cells,
called E26-“MEPs” for “Myb-Ets transformed progeni-
tors,” resemble normal MEP cells in that they can be in-
duced to differentiate into megakaryocytes and erythro-
cytes by the inactivation of either the Myb or Ets domains
of the Myb-Ets oncoprotein (7–9). Enforced C/EBP
 
 
 
 or
 
 
 
 expression mimics the phorbolester effect, leading to the
formation of eosinophils through a partial down-regula-
tion of GATA-1 (10, 11). In contrast, PU.1 induces these
cells to mature into myeloblasts through a complete
down-regulation of GATA-1 (12). This process is revers-
ible as enforced expression of GATA-1 in myeloid cells
leads to the formation of eosinophils when expressed at
low levels and of MEP cells, when expressed at high levels
(13; Fig. 2 B).
There is yet another player in this process: FOG-1. This
“Friend of GATA-1” protein, which was first identified as
a GATA-1 binding protein, is essential for megakaryocyte
formation (14). It is expressed in normal cells as well as in
E26-transformed MEPs but not in eosinophils and myeloid
cells. Importantly however, its enforced expression in eo-
sinophils induces them to “de-differentiate” into MEPs,
while the factor has no effect on myeloblasts (15). As is the
case in the induction of eosinophils from human cord
blood cells (2) the NH
 
2
 
-terminal zinc finger, which binds
FOG-1, is not required for the switch (14). Thus, in this
transformed cell system, lineage transitions can be induced
according to a simple binary code that defines cell identity:
intermediate levels of GATA-1 plus C/EBP
 
 
 
/
 
 
 
 specifies
eosinophils; high GATA-1 plus FOG-1 specifies MEPs;
and PU.1 plus C/EBP
 
 
 
 specifies myeloblasts (Fig. 2). In
addition to these synergisms, two types of cross-antago-
nisms play an essential role in the process of determining
whether a cell differentiates along the eosinophil or my-
eloid pathway: C/EBP and FOG-1 on the one hand and
PU.1 and GATA-1 on the other. These antagonisms
which are discussed in more detail elsewhere (9, 16, 17) but
both ensure that active commitment to one cell fate coin-
cides with a repression of other cell fates.
 
GATA and C/EBP Cooperate on Eosinophil-specific Promot-
ers.
 
Key to deciphering the process that governs eosino-
phil lineage commitment at the molecular level has been
the dissection of transcriptional control elements that reg-
ulate eosinophil-specific genes (18–20). A well studied ex-
ample is the eos47 gene (encoding EOS47, the avian
ortholog of the mammalian melanotransferrin gene)
which in bone marrow is specific to early eosinophils (21).
The elements governing its lineage-specific expression re-
side within a 309 bp promoter region and consist of bind-
ing sites for Myb-, Ets-, C/EBP-, and GATA-type tran-
scription factors. C/EBP
 
 
 
 and Ets-1 were found to
cooperate in both the binding to and activation of the
eos47 promoter, mediated through an interaction be-
tween the DNA-binding domains of the factors (18). In-
terestingly, while low levels of GATA-1 enhanced pro-
moter activation by C/EBP
 
 
 
 and Ets-1, high levels led to
a repression (which was further enhanced by FOG-1),
with GATA-1 on its own having little effect (15). Thus,
Figure 1. Two models explaining how GATA-1 and C/EBP might
induce eosinophil formation in CD34  cells. 
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positive and negative regulation of the EOS47 promoter
by GATA, C/EBP, and FOG-1 closely mimics their ef-
fects on cell phenotype: here also, moderate levels of
GATA-1–induced eosinophil formation while high levels
of GATA-1, as well as FOG-1, led instead to the forma-
tion of MEP cells (11, 13, 15, 18). Unlike C/EBP and
GATA factors, Ets-1 and c-Myb, because of their wide-
spread distribution across the hematopoietic system, prob-
ably contribute to basal promoter activity and do not ap-
pear to directly participate in lineage specification of
eosinophils.
Studies of the mammalian granule major basic protein
(MBP) promoter, likewise, showed a cooperative effect of
C/EBP
 
 
 
 and GATA-1 (19, 20). Here also FOG-1 was
found to lead to a repression of the promoter (15, 19).
Taken together, these results strongly support the eosino-
phil-specific combinatorial code that has emerged from the
enforced expression experiments discussed before.
Figure 3. Roads to eosinophil formation.
The scheme, which is based on work by
Akashi et al. (reference 26) shows combina-
torial transcription factor codes that specify
GMPs and MEPs on the one hand, and
eosinophils on the other. It also depicts al-
ternative pathways of eosinophil formation
during normal hematopoiesis. CMP, common
myeloid progenitor; GMP, granulocyte/
macrophage progenitor; MEP, megakaryo-
cyte/erythroid progenitor; Mac, macrophage;
Gran, neutrophil granulocyte; Eos, eosino-
phil; Ery, erythrocyte; Meg, megakaryocyte.
Figure 2. Generation of eosinophils in trans-
formed cells. (A) E26 leukemia virus transformed
MEPs can be induced to differentiate into either
eosinophils or myeloblasts by phorbolester treat-
ment, depending on whether protein kinase C
(PKC) activity is high or low. (B) The three types
of E26 transformed cells can be converted into one
another (arrows) by enforced expression of the
transcription factors indicated. 
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Which of the GATA and C/EBP Family Members Are the
Key Players In Vivo?
 
As GATA-1, GATA-2, C/EBP
 
 
 
,
and C/EBP
 
 
 
 are all known to be expressed in eosinophils
and to have the capacity to induce eosinophil formation,
do they all play a role in eosinophil formation in vivo?
Studies with knockout mice suggest that this is not so and
that the key players are in fact GATA-1 and C/EBP
 
 
 
.
Thus, mice lacking C/EBP
 
 
 
 show a profound absence of
neutrophils and eosinophils (22). Although GATA-1 is es-
sential for the formation of erythroid and megakaryocytic
cells, more recent data suggest that it is also essential for the
formation of eosinophils. In this issue, Hirasawa et al. show
that GATA-1–deficient fetal liver cells lack the ability to
form eosinophils unless GATA-1 (or GATA-2) is reintro-
duced into these cells (2). Similarly, in another article in
this issue, Yu et al. (23) describe a regulatory element in the
GATA-1 promoter that selectively governs expression of
this gene in eosinophils. Disruption of this element leads to
the formation of mice that completely lack eosinophils. In-
terestingly, these mice still have (immature) mast cells (23).
In contrast, earlier work of the same group had shown that
GATA-2 knockout mice display a general reduction of he-
matopoiesis, but a complete lack of mast cells (24). A role
of GATA-2 in mast cell formation is also supported by the
observation that GATA-2, but not GATA-1, induces the
formation of mast cells in multipotent progenitors, in con-
junction with moderate levels of PU.1 (Singh, H., personal
communication). In aggregate, these experiments indicate
that GATA-1 together with C/EBP
 
 
 
 is the key player for
the formation of eosinophils in vivo while GATA-2 is cru-
cial for the formation of mast cells.
 
Normal Origins of Eosinophils.
 
Eosinophils developed
relatively late during vertebrate evolution, perhaps by the
“recycling” of transcription factors that had been “in-
vented” earlier. This may have occurred through the in-
troduction of thresholds that play out on novel, eosino-
phil-specific promoters, such as that described in the study
by Yu et al. (23) see also Nerlov et al. [25]). A possible sce-
nario of how transcription factors specify myeloid and
erythroid lineages and how eosinophils might fit into this
scheme is shown in Fig. 3, based on the evidence discussed
above as well as the known expression patterns of these
factors in normal hematopoietic progenitors (26). In this
scenario CMPs coexpress a number of lineage-restricted
factors such as GATA-1/FOG-1 on the one hand and
PU.1/C/EBP on the other, reflecting the concept of
“priming” that has been suggested by Enver and colleagues
(27). Lineage decisions would then ensue by the up-regu-
lation of one program (PU.1/C/EBP for myeloid cells and
GATA-1/FOG-1 for erythroid cells) and would be stabi-
lized by the GATA-1/PU.1 and FOG-1/C/EBP cross-
antagonisms. In this model eosinophils represent a cellular
intermediate which is specified by moderate levels of
GATA-1 together with C/EBP
 
 
 
 and the absence of
FOG-1 (for reviews, see references 9, 16, and 17). It is less
clear how eosinophils originate during normal hematopoi-
etic differentiation. One speculation, akin to model B in
Fig. 1, is that they form as a separate branch from either
GMPs or MEPs (indicated by the top and bottom arrows
in Fig. 3). Alternatively, they may form from CMPs (mid-
dle arrow in Fig. 3). Recent work by Akashi and col-
leagues has shown that both CMPs and GMPs can gener-
ate eosinophil colonies in the presence of IL-3, SCF, and
IL-5, while MEPs do not (Koichi Akashi, personal com-
munication). This would suggest that the third route, con-
version from MEPs into eosinophils via up-regulation of
C/EBP
 
 
 
 is not normally used.
Along with the understanding of how eosinophils are
generated comes the potential for new therapies of allergic
diseases and asthma. Eosinophils are known to be major
mediators of lung tissue damage in chronic allergy. Prevent-
ing their influx and ability to degranulate has been explored
as a potential point for therapeutic intervention. Tissue-spe-
cific inhibition of either C/EBP
 
 
 
 or GATA-1 function,
such as by expression of antisense/dominant negative forms
in erythroid/myeloid progenitors or of FOG-1 in eosino-
phils, may offer a means of blocking eosinophil formation.
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